University of Health Sciences, Izmir Bozyaka Training and Research Hospital, Department of Internal Medicine - Izmir, Turkey.
Rev Assoc Med Bras (1992). 2022 Jun 24;68(6):820-826. doi: 10.1590/1806-9282.20211215. eCollection 2022.
Polycystic ovary syndrome is the most common endocrinopathy among women of reproductive age. Polycystic ovary syndrome is a metabolic disorder associated with insulin resistance and subclinical inflammation. Dermcidin, an antimicrobial peptide, involves in insulin resistance and inflammatory processes. Dermcidin suppresses the secretion of insulin production from the liver/pancreas and also increases insulin resistance. We aimed to discover whether dermcidin levels were altered in polycystic ovary syndrome women compared to controls and determine the link of dermcidin with hormonal-metabolic parameters in polycystic ovary syndrome women.
The current research was designed as a case-control study and Rotterdam 2003 criteria were used for diagnosing polycystic ovary syndrome. A total of 75 subjects with polycystic ovary syndrome and 75 age- and body mass index-matched subjects as controls were enrolled in the study. The insulin resistance state was determined using a homeostatic model assessment of insulin resistance and quantitative insulin sensitivity check index. High-sensitivity C-reactive protein levels were assessed to define inflammation.
Circulating dermcidin levels were measured by enzyme-linked immunosorbent assay. Dermcidin levels were significantly increased in polycystic ovary syndrome subjects compared to controls (172.53±42.41 ng/mL vs. 108.44±31.69 ng/mL, p<0.001). Homeostatic model assessment of insulin resistance and high-sensitivity C-reactive protein levels were markedly increased, whereas quantitative insulin sensitivity check index levels were notably decreased in women with polycystic ovary syndrome compared to controls. Linear regression analysis revealed that dermcidin exhibited an independent link with homeostatic model assessment of insulin resistance and high-sensitivity C-reactive protein, whereas dermcidin displayed an inversely independent link with quantitative insulin sensitivity check index.
Increased dermcidin levels were associated with insulin resistance and inflammation in polycystic ovary syndrome women, suggesting that dermcidin may play a role in the pathophysiology of polycystic ovary syndrome.
多囊卵巢综合征是育龄妇女中最常见的内分泌疾病。多囊卵巢综合征是一种与胰岛素抵抗和亚临床炎症相关的代谢紊乱。抗菌肽 Dermcidin 参与胰岛素抵抗和炎症过程。Dermcidin 抑制肝脏/胰腺胰岛素的产生和分泌，并增加胰岛素抵抗。我们旨在研究多囊卵巢综合征妇女与对照组相比，Dermcidin 水平是否发生改变，并确定多囊卵巢综合征妇女中 Dermcidin 与激素代谢参数的关系。
本研究设计为病例对照研究，采用 2003 年鹿特丹标准诊断多囊卵巢综合征。共纳入 75 例多囊卵巢综合征患者和 75 例年龄和体重指数匹配的对照组患者。采用稳态模型评估胰岛素抵抗和定量胰岛素敏感指数检查来确定胰岛素抵抗状态。采用高敏 C 反应蛋白水平来定义炎症。
通过酶联免疫吸附试验测定循环 Dermcidin 水平。与对照组相比，多囊卵巢综合征患者的 Dermcidin 水平显著升高（172.53±42.41ng/ml 比 108.44±31.69ng/ml，p<0.001）。与对照组相比，多囊卵巢综合征患者的稳态模型评估胰岛素抵抗和高敏 C 反应蛋白水平显著升高，而定量胰岛素敏感指数检查水平显著降低。线性回归分析显示，Dermcidin 与稳态模型评估胰岛素抵抗和高敏 C 反应蛋白呈独立正相关，而与定量胰岛素敏感指数检查呈独立负相关。
多囊卵巢综合征妇女中 Dermcidin 水平升高与胰岛素抵抗和炎症有关，表明 Dermcidin 可能在多囊卵巢综合征的病理生理学中发挥作用。
